Wugen Takes $172M For Tumor Treatments
socalTECH
JULY 20, 2021
San Diego-based Wugen, a biotechnology company which is developing treatments for solid tumors, recently annoucned a $172M, Series B funding round. The company--which says it licensed its technology from Washington University in St. Louis--said the Series B was co-led by Abingworth and Tybourne Capital Mangaement, and also included Fidelity Management & Research Company, Intermediate Capital Group (ICG), Sands Capital, Aisling Capital Management, Alexandria Venture Investments, Velosity Capital
Let's personalize your content